

First Berlin Equity Research publishes first coverage of bioXXmed AG with buy recommendation

Darmstadt, 2 August 2023 - First Berlin has initiated coverage of bioXXmed. Based on current developments and forecasts, Christian Orquera comes to an assessment of the share's potential as a "speculative buy" with a price target of € 3.10.

This analysis is based on the current analyses of the effect and potential of DermaPro®. At the general meeting of bioXXmed AG this Friday, the shareholders will be informed about the development status and business development activities.

The analysis shows that the market development in India is slower than predicted in earlier years, but that the upside potential in Europe and the USA is given.

The complete study is available for download at <https://bioxxmed.ag/wp-content/uploads/2023/07/First-Berlin-Research-31-07-2023.pdf>.

About bioXXmed AG

bioXXmed AG is an investment company that holds 66.92% in DermaTools Biotech GmbH and 49.96% in CytoPharma GmbH.

Disclaimer

This release may contain forward-looking statements. Such forward-looking statements reflect the opinion of bioXXmed as of the date of this communication based on certain assumptions and expectations. Actual future developments and the results actually achieved by bioXXmed may differ materially from the forward-looking statements. bioXXmed is under no obligation to update or revise any forward-looking statements.

Contact:

bioXXmed AG

Dr. Bruno Rosen

Riedstrasse 2

64295 Darmstadt

Phone: +49-6151 951 581 2

E-mail: kontakt@bioxxmed.ag